Latest rheumatoid arthritis Stories
PETACH TIKVA, Israel, Nov. 18, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd.
- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies
- Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies EAST HANOVER, N.J., Nov.
~Data to be presented at the American College of Rheumatology Annual Meeting CHARLOTTESVILLE, Va., Nov.
Be Joint Smart to educate roughly 48,000 local residents with PsA about their disease PORTLAND, Ore., Nov.
- Four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014 EAST HANOVER, N.J., Nov.
VANCOUVER, Nov. 5, 2014 /PRNewswire/ - Augurex Life Sciences Corp.
Payers Employ a Variety of Cost-Control Measures to Manage the Utilization of Premium-Priced RA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
New endurance program unites psoriatic disease community and cycling enthusiasts to find a cure PORTLAND, Ore., Oct.
Achieve Clinical Research recently opened up a new clinical trial, and they are looking to enroll individuals who are suffering from clinically relevant arthritis pain.